Evidence map›Paper›PMID 34221387›Full record

ArticleClinical kidney journal2021

Pro-calcifying analysis of uraemic serum from patients treated with medium cut-off membrane in a prospective, cross-over study.

Paola Ciceri, Giorgia Tettamanti, Andrea Galassi, Lorenza Magagnoli, Nicolas Fabresse, Jean-Claude Alvarez, Ziad A Massy, Piergiorgio Messa, Mario Cozzolino

Open access · goldAbstract read
In one paragraph

Article in Clinical kidney journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The role of the kynurenine pathway in cardiovascular disease.Frontiers in cardiovascular medicine · 2024
    Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Paola CiceriDepartment of Nephrology, Dialysis and Renal Transplant, Renal Research Laboratory, Fondazione Ca' Granda IRCCS, Ospedale Maggiore Policlinico, Milan, Italy.
Giorgia TettamantiDepartment of Health Sciences, Renal Division, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.
Andrea GalassiDepartment of Health Sciences, Renal Division, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.
Lorenza MagagnoliDepartment of Health Sciences, Renal Division, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.
Nicolas FabresseLaboratory of Pharmacology and Toxicology, CHU Raymond Poincare, Garches, France.
Jean-Claude AlvarezLaboratory of Pharmacology and Toxicology, CHU Raymond Poincare, Garches, France.
Ziad A MassyDivision of Nephrology, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt/Paris, Paris, France.
Piergiorgio MessaDepartment of Nephrology, Dialysis and Renal Transplant, Renal Research Laboratory, Fondazione Ca' Granda IRCCS, Ospedale Maggiore Policlinico, Milan, Italy.
Mario CozzolinoDepartment of Health Sciences, Renal Division, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.ORCID https://orcid.org/0000-0002-8494-6252
University of Milan · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITInserm · FRHôpital Raymond-Poincaré · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe retention of a large number of solutes that are normally excreted or metabolized by the kidney is responsible for the symptoms typical in uraemic patients. These molecules are defined as uraemic toxins and can be classified into three groups: small water-soluble molecules, middle molecules and protein-bound toxins. Recently, efforts were put towards developing dialysis membranes that allow the removal of large middle molecules without clinically relevant albumin loss. These membranes are the medium cut-off (MCO) membranes that allow the removal of middle molecules up to ∼50 000 Da.

methodsWe performed a prospective, open-label, controlled, cross-over pilot study comparing expanded haemodialysis (HDx) (novel MCO membrane Theranova 400) and conventional haemodialysis (HD) in 20 prevalent HD patients. Ten patients used conventional HD high-flux dialyser and 10 patients used HDx for 3 months; later the patients switched and received the other treatment for a further 3 months. We then analysed the pro-calcifying effect of uraemic serum in a model of high phosphate(Pi)-induced calcification in vascular smooth muscle cells (VSMCs).

resultsIn this study, every patient was the control of himself and, interestingly, we found a tendency of less pro-calcifying potential from HDx-treated patients' serum compared with HD. Studying pathogenetic processes involved in high Pi-induced calcium deposition, we found that uraemic serum of HDx-treated patients induced less VSMC necrosis compared with uraemic serum of HD patients. Nevertheless, no differences were found between the different dialytic treatments in the serum potential to induce apoptosis and to modulate the expression of a panel of genes involved in VSMC simil-osteoblastic differentiation such as bone morphogenetic protein 2, runt-related transcription factor 2, osteocalcin, matrix Gla protein, osteopontin, elastin and collagen I α1. In an effort to characterize the difference in uraemic toxin profile during the two different dialytic treatments, we measured a panel of 10 uraemic toxins and 3 precursors, finding a significant increased removal during HDx of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, tryptophane and some of its metabolites, such as 3-indoxyl sulphate, indole 3-acetic acid and kynurenine.

conclusionsThese preliminary data are promising, although larger patients' groups are needed to better understand the effects of HDx on vascular calcification.

Indexed as

necrosisprotein-bound uraemic toxinsuraemic serumvascular calcification

Identifiers

PMID34221387
PMCPMC8243281
OpenAlexW3108821195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.